Public tenders for vaccination in United States

Find all Medical tenders in the world.
Finding business opportunities has never been easier.

Results for medical. Make a new search!
MedicalvaccinationUnited States

Vaccination Capacity Inventory of Community Health Centers

Department of Health and Human Services, Centers for Disease Control and Prevention | Published March 28, 2017  -  Deadline April 11, 2017
cpvs

The Centers for Disease Control and Prevention, NCIRD/ISD, 1600 Clifton Rd. NE, Atlanta, GA, 30333, hereby announces its intent to issue a sole source contract in accordance with FAR 6.302-1 to National Association of Community Health Centers, 7501 Wisconsin Ave, Suite 1100 W, Bethesda, MD 20814, to perform a nationwide assessment of current vaccination activities and capacity to provide vaccination services in federally funded community health centers. Community health centers (CHCs) served 24 million Americans in 2015 in over 9,000 locations across all 50 U.S. states. By statute, CHCs serve primarily low-income uninsured or other medically underserved patients, making them an important partner in providing access to vaccination for hard-to-reach populations, particularly in states that have not expanded their Medicaid programs following passage of the Affordable Care Act. CHCs are often discussed as part of the immunization neighborhood, but little is known about the extent to which they currently provide vaccination services to their patient panels, nor their capability to expand current vaccination offerings. A baseline inventory of the current practices and capacities of the national CHC network could inform future collaborations to increase vaccination access in underserved populations in addition to providing a clearer picture of how CHC patients currently access vaccination services.Partnering with the National Association of Community Health Centers (NACHC) to field a representative survey of CHCs nationwide. CDC would provide technical assistance for drawing a randomized sample of the NACHC membership and developing a survey instrument to examine clinic characteristics and practices relating to provision of vaccination services in CHCs. Research and collaboration with outside groups is a major element of NACHC's stated mission, and the organization has the capacity to work with state-level networks of CHCs to maximize survey participation. ISD has a strong existing relationship with NACHC via the Communication and Education Branch, which currently manages a project focusing on increasing adult vaccination in CHCs by improving integration of CHC health records with IIS in a small number of states.NACHC is uniquely positioned to partner with CDC in this study due to their decades-long history of providing operational, educational, research, and advocacy support to America's medically underserved and underinsured. Research and collaboration with outside groups is a major element of NACHC's stated mission, and the organization has the capacity to work with state-level networks of CHCs to maximize survey participation. ISD has a strong existing relationship with NACHC via the Communication and Education Branch, which currently manages a project focusing on increasing adult vaccination in CHCs by improving integration of CHC health records with IIS in a small number of states.No other organization works with state and regional primary care associations, health center controlled networks, and specifically the national organization representing community health centers. Responsible sources that believe they possess the expertise and capabilities identified above are encouraged to submit to the Contracting Officer within 15 days from the posting date of this notice, their written capabilities statement which shall be considered by the agency. Please forward the capability statement information to Maria Shamburger, Contracting Officer, Reference 2017-10201, Centers for Disease Control, Office of Acquisition Services, ATTN: Maria Shamburger, MS: K14, 2920 Brandywine Road, Atlanta, GA 30341. All vendors must be registered in the System for Award Management (SAM) prior to an award of a federal contract. The website is: www.sam.gov.  

Evaluation of a Thermostable Microneedle Patch for Measles Vaccination to Overcome Inhibition from Maternal Antibody

Department of Health and Human Services, Centers for Disease Control and Prevention | Published July 31, 2014  -  Deadline August 17, 2015
cpvs

THIS NOTICE IS FOR INFORMATIONAL PURPOSES ONLY. The Centers for Disease Control and Prevention (CDC), National Center for Immunization and Respiratory Diseases (NCIRD), contemplate award of a Firm Fixed Price Sole Source Contract to the University of California. The work shall be performed at the Contractor's facility. The Period of Performance shall be for 12 months. The North American Industrial Classification Standards (NAICS) Code is 541990 and Standard Business Size of $15M. Contract #200-2014-60103, Line Item #1 will be awarded to the University of California by 8/21/2015. The sole source award will be conducted in accordance with FAR Part 6.302-1 only one responsible source and no other supplies or services will satisfy agency requirement. This requirement is new requirement. To reduce measles morbidity and mortality, this project has two long-term goals: to improve measles vaccine immunogenicity by targeting vaccine delivery to the skin and to improve measles vaccination coverage by simplifying logistics of mass vaccination using a microneedle patch. Although measles vaccine is highly efficacious in older children and adults, vaccination of infants under the age of 9 months is much less effective due to inhibition of the immune response by maternal antibodies. Previous studies by our collaborators and others have shown that skin vaccination generates qualitatively and quantitatively different and more robust immune responses compared to subcutaneous or intramuscular vaccination of a number of different vaccines. This study will test the hypothesis that skin vaccination using a microneedle patch in infant rhesus macaques with maternal antibody generates a strong immune response that is protective against live measles virus challenge. In that context, this study will also test the hypothesis that a microneedle patch can be developed to (i) administer a full human dose of measles and rubella vaccines, (ii) maintain vaccine activity after extended storage at elevated temperature, (iii) enable simple administration with minimal training and (iv) generate no sharps waste after use in order to simplify logistics of mass vaccination and thereby increase vaccination coverage. The overall goal is to develop a thermostable MR patch for simple skin vaccination and assess protective efficacy of measles vaccination in the infant rhesus macaque with maternal antibody. Non-human primates are a good model to evaluate the immunogenicity of measles vaccines. Rubella vaccine will also generate an immune response in non-human primates. CDC is not requesting competitive proposals and no solicitation is available. Firms that believe they can provide the services required are encouraged to identify themselves and give written notification to the Contracting Officer no later than 2:00 PM Eastern Standard Time, by August 17, 2014. Determination not to compete this proposed action based on responses to this notice is solely within the discretion of the Government. Respondents will assume all financial costs for preparing a response to this notice. The U.S. Government assumes no financial obligation for the preparation and distribution of prepared responses. Inquiries may be sent to Monica Shaw via email at vwk1@cdc.gov.

R--Retail Influenza Vaccination

Department of Veterans Affairs, VA Denver Acquisition & Logistics Center | Published May 24, 2017  -  Deadline June 14, 2017
cpvs

THIS IS A PRE-SOLICITATION NOTICE. The Request for Proposal (RFP) Number will be VA-791-17-R-0091. The Department of Veterans Affairs, Denver Acquisition and Logistic Center (DALC), 555 Corporate Circle, Golden, CO 80401, intends to solicit for offers from qualified and experienced retail pharmacies with nationwide coverage through full and open competition. The intent of the RFP will be to award multiple indefinite delivery / indefinite quantity contracts for influenza immunization services throughout the United States. VA is advancing the convenience of providing immunizations at retail providers locations, combined with integrated immunization health records to significantly increase access to influenza vaccinations and improving overall immunization rates for Veterans. Specifically, VA is working to provide a more accurate real time view of Veteran immunizations with the objective of early identification of high risk Veterans who have not received a flu shot. Government s requirements are per the following: Provide influenza (flu) vaccinations to eligible Veterans at nationwide retail pharmacy stores; Transmit immunization data in information primarily displayed as a summary with a generated document known as a Continuity of Care Document (C-CDA, C32, and/or C62) as well as any associated clinical notes through an eHealth Exchange Certified Gateway to VA compliant with SequiaProject.org Push standard specification; Provide training to Contractor pharmacist about correct data entry, processing and submission of Veteran immunization data from the Contractor health record system to the VA; Compliance with all regulatory, privacy and safety regulations required for providing healthcare services; and Plan and execute an advertising campaign to promote Veteran influenza immunizations. Retail pharmacies must be Medicare certified, capable of providing, delivering, supervising, and monitoring immunization services. The Government intends to execute multiple contracts with a base period of eight months with one options year. This acquisition will be conducted as a full and open competition for any and all qualified, experienced, and knowledgeable business entities, whose offers represent the acceptable ratings for Technical Qualification, Past Performance, and prices for the base and option period that are considered fair and reasonable. The North American Industry Classification System is 446110, All Other Miscellaneous Ambulatory Health Care Services. The Small Business Size Standard is $27 million. Solicitation documents will be available electronically in the near future through the Federal Business Opportunities System (FedBizOpps) website at http://www.fedbizopps.gov. The anticipated closing date is June 14, 2017. The Contracting Officer for this acquisition is David Little. Community providers interested in responding to this solicitation should provide their email addresses and contact information to david.little@va.gov and/or caroline.west@va.gov. Upon review of the solicitation documents, prospective offerors are encouraged to provide questions and/or comments in writing. All contractors must be registered System for Award Management (SAM) website as an active contractor in order to be eligible to enter into a contract and to receive payments. The SAM website is found at https://www.sam.gov/portal/public/SAM. Please be sure your company is registered at this website. Prospective offerors should complete electronic annual representations and certifications, which is also part of the SAM. Due to the limited time offerors have to respond you are encouraged, but not required, to register in advance. THIS IS NOT A REQUEST FOR PROPOSALS, QUOTATIONS OR BIDS. THE VA DALC IS NOT SEEKING PRICING OR OFFERS OF ANY KIND AT THIS TIME. THE VA RESERVES THE RIGHT TO SOLICIT THESE ITEMS FROM LARGE OR SMALL BUSINESSES, AS APPROPRIATE.

Evaluation of maternal vaccination in a high-risk population

Department of Health and Human Services, Centers for Disease Control and Prevention | Published July 7, 2016  -  Deadline July 22, 2016
cpvs

The Centers for Disease Control and Prevention, NCIRD/ISD/PO, 1600 Clifton Rd. NE, Atlanta, GA, 30333, hereby announces its intent to issue a sole source contract in accordance with FAR 6.302-1 to Johns Hopkins Center for American Indian Health, 415 N. Washington Street 4th Floor, Baltimore, MD 21231 to perform a study to understand facilitators and barriers to maternal vaccination and to use this information and new communication technologies to promote vaccine uptake in vulnerable populations by assessing current levels of vaccination and factors associated with HCP recommendation and maternal receipt of influenza and pertussis vaccine, developing and disseminating messages to promote maternal immunization, and evaluating the impact of these interventions on uptake of Tdap and influenza vaccines among pregnant women. The Johns Hopkins Center for American Indian Health has over 25 years of experience working with American Indian Communities. They currently support 10 field offices in 4 tribal communities, and support the development, implementation and evaluation of public health activities to improve the health of Native communities. They are a trusted partner, and have existing relationships with clinics, schools, community-based organizations and other partners in tribal communities. They have conducted research on numerous health interventions in partnership with tribes, and have published numerous studies in peer-reviewed journal articles. The Johns Hopkins Center for American Indian Health (CAIH) is well versed in the IHS clinical infrastructure and the data systems employed by IHS, including the Resource and Patient Management System (RPMS). This knowledge is essential for developing and validating an algorithm using the IHS electronic health record. In addition, developing a provider reminder and evaluating the impact of the reminder requires knowledge of the appropriate data sources and data elements and an understanding of the IT and clinic flow processes currently used in IHS healthcare settings. CAIH is currently conducting clinical studies in many service units and its facilities are co-located on the IHS hospital grounds or at a nearby accessible location. CAIH staff have undergone IHS training and background checks and are able to access RPMS. In addition, CAIH has partnered with IHS for evaluation and implementation of numerous evidence-based programs (e.g., the Family Spirit maternal and child health home visiting program, suicide prevention, diabetes prevention). Johns Hopkins has extensive experience working to address the burden of infectious diseases in American Indian communities, and has developed particular expertise in the area of vaccine-preventable diseases. They have led clinical trials in tribal communities for vaccines to prevent Haemophilus influenzae type B (Hib), Streptococcus pneumoniae, and rotavirus. In addition, CAIH demonstrated the effectiveness of maternal influenza vaccine in AI/AN populations for prevention of infant influenza-associated hospitalizations. CAIH's depth and breadth of experience in evaluating vaccines and specific expertise in the area of maternal immunizations, along with their experience conducting mixed-methods research in American Indian communities will be critical to the success of this project. There are no other organizations that can simultaneously provide experience in conducting research with tribes, working with Indian Health Service, and experience with vaccine research. They also have an existing infrastructure in place in tribal communities.Responsible sources that believe they possess the expertise and capabilities identified above are encouraged to submit to the Contracting Officer within 15 days from the posting date of this notice, their written capabilities statement which shall be considered by the agency. Please forward the capability statement information to Maria Shamburger, Contracting Officer, Reference 2016-96324, Centers for Disease Control, Office of Acquisition Services, ATTN: Maria Shamburger, MS: K14, 2920 Brandywine Road, Atlanta, GA 30341. All vendors must be registered in the System for Award Management (SAM) prior to an award of a federal contract. The website is: www.sam.gov.The Government will review any/all capabilities statements submitted and determine if other qualified sources do exist that could provide this requirement. Information received in response to this announcement will be used solely for the purpose of determining whether to conduct a competitive procurement.If no affirmative responses are received within 15 days, negotiations will be conducted with the Johns Hopkins Center for American Indian Health as the only source and a contract will be issued without any additional notices being posted.

F--WH&B Trimming and Vaccination

Department of the Interior, Bureau of Land Management | Published September 22, 2015
cpvs

IGF::OT::IGF WH&B TRIMMING CONTRACT

65--VACC Vaccination Workstation

Department of Veterans Affairs, Long Beach VANLO | Published September 11, 2010  -  Deadline September 17, 2010
cpvs

This is a COMBINED SYNOPSIS/SOLICITATION for commercial items prepared in accordance with the format in Subpart 12.6, Streamlined Procedures for Commercial Items, as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; quotes are being requested and a written solicitation will not be issued. The solicitation number VA-262-10-RQ-0527 is issued as a request for quote (RFQ) as a brand name or equal. Brand name or equal description is intended to indicate the quality and characteristic of products that will be considered satisfactory to meet the agency requirements. No telephone requests will be accepted. This solicitation incorporates provisions and clauses as those in effect through Federal Acquisition Circular 2005-43. The North American Industry Classification System Code (NAICS) is 621493 - Freestanding Ambulatory Surgical and Emergency Centers and the Small Business Standard is $10.0 million. Line Item 01: 3 EA - UNIT PRICE $ _______________, TOTAL PRICE $ _______________. 5,000 Person Vaccination WorkStation (Model PVS-5-RF) Brand name or equal The 5,000 Person Vaccination WorkStation must include all of the following or equal components (1) 42" Vaccination Workstation with Built-in Refrigerator & Table with complete Vaccination System, which consists of: (a)Workstation Specifications " Length 43 inches " Height 48 inches " Width 24 inches " Drawers 3 or more -100 lbs. capacity each " Fold-Out table 7 sq. ft. work surface " Tilt Bins - Each 9.5"L x 3.5"W " Wheel Base 18.5"W x 36"L " Wheels 4"D x 2"W " Detachable table for instant work space (b) Refrigerator Specifications " Dimensions 17.875"W x 32.635"H x 19.125"D " Capacity 2.9 cubic feet " Voltage 110V/ 60Hz standard © Vaccination System " (1) Certified traceable thermometer to monitor vaccine cold chain management " (3) Wheeled medical re-supply cases " (5,300) Nitrile exam gloves " (4,200) 23 g x 1" 3cc. safety syringes " (1,100) 22g x 1.5 cc safety syringes " (1) Calculator " (1) Nurses' Drug Reference " (5) Sharps Containers " (5,400) 2x2 Gauze Sponges " (6) Biohazard spill kits " (5400) Alcohol pads " (10) Hand Sanitizer (8 oz. bottles) " (5300) Sheer spot bandages " (640) Canisters surface sanitizer wipes " (1) Biohazard waste container & lid " (75) Biohazard waste bags Delivery charges must be incorporated into the line item prices. Delivery of equipment shall be F.O.B. Destination to the VA MEDICAL CENTER, 3350 LA JOLLA VILLAGE DR, San Diego, CA 92161-0002 US, within consignee's premises. At the time of delivery, the equipment and all associated equipment shall be new, free from defects and in good working condition. Re-manufactured equipment will not be accepted. Offerors must comply with all instructions contained in provision 52.212-1 Instructions to Offerors - Commercial Items. Pursuant to FAR Clause 52.212-4, para (t), Central Contractor Registration (CCR), after initial registration, the contractor is required to update registration data as changes occur and must re-register annually to ensure all data remains current. Noncompliance with this requirement will preclude the exercising of any option periods that may be included herein and will be cause for termination of the contract at such time noncompliance is discovered. Refer to cited Clause for more details. You are required to register with the CCR database at the following web address: CCR - http://www.ccr.gov. It is imperative that you complete this registration in order to be considered for contract award. In accordance with FAR Provision 52.212-1 paragraph (j), please provide the Dun and Bradstreet Number assigned to your firm in the space provided: DUNS# __ __ - __ __ __ - __ __ __ __. 52.212-3 Offerors Representations and Certifications - Commercial Items - THE CONTRACTOR MUST RETURN A COMPLETED COPY OF PROVISION 52.212-3 WITH THE OFFER, a copy of the provision may be attained from https://www.acquisition.gov/Far/ 52.212-4 Contract Terms and Conditions - Commercial Items (10/03) 52.212-5 Contracts Terms and Conditions Required to Implement Statutes or Executive Orders - Commercial Items. The following FAR clauses identified at paragraph b of FAR 52.212-5 are considered checked and are applicable to this acquisition: 1, 22, 31, 34, 39. The following additional clauses and provisions apply: FAR 52.204-7 Central Contractor Registration ; FAR 52.211-6 Brand Name or Equal; FAR 52.232-18 Availability of Funds; FAR 52.233-2 Service of Protest; VAAR 852.211-71(a) Guarantee; VAAR 852.211-77 Brand Name or Equal; VAAR 852.270-4 Commercial Advertising; VAAR 852.237-70 Contractor Responsibilities. This contract incorporates one or more clauses by reference, with the same force and effect as if they were given in full text. This solicitation incorporates one or more solicitation provisions by reference, with the same force and effect as if they were given in full text. Upon request, the Contracting Officer will make their full text available. The offeror is cautioned that the listed provisions may include blocks that must be completed by the offeror and submitted with its quotation or offer. In lieu of submitting the full text of those provisions, the offeror may identify the provision by paragraph identifier and provide the appropriate information with its quotation or offer. The full text of a clause and provision may be accessed electronically at this/these addresses: Federal Acquisition Regulation Home Page: https://www.acquisition.gov/Far/; Veterans Affairs Acquisition Regulation Home Page: http://www1.va.gov/oamm/oa/ars/policyreg/vaar/. Warranty information shall be provided. Technical in-service training shall be provided at no additional cost to the Government. Defense Priorities and Allocations System (DPAS) and assigned rating, are not applicable to this acquisition. The Government will consider all quotes received by 5:00 PM PST September 17, 2010. Offers may be emailed to Christy Glass, at Christy.Glass@va.gov with "VACC Vaccination Workstation" in the subject title.

Wild Horse Trimmings and Vaccinations

Department of the Interior, Bureau of Land Management | Published June 3, 2015  -  Deadline June 18, 2015
cpvs

WH&B TRIMMING and VACCINATION CONTRACT This is a combined synopsis/solicitation for commercial items and services prepared in accordance with the format in Subpart 12.6 as supplemented with additional information included in this notice. This announcement constitutes the only solicitatoin; quotes are being requested and a written solicitation will not be issued.

Impact of Rotavirus Vaccination

Department of Health and Human Services, Centers for Disease Control and Prevention | Published June 4, 2009  -  Deadline June 30, 2009
cpvs

The Centers for Disease Control and Prevention (CDC) intends to award, on a sole source basis, a contract to University of Washington, Children's Hospital & Regional Medical Center, 4800 Sand Point Way, NE, Mailstop B-5520, Seattle, WA 98105. The purpose of the contract is to obtain data on the incidents of rotavirus in children < 5 years of age and the vaccination rate associated with those incidents. Justification for other than full and open competition is considered due to the fact that only Seattle Children's Hospital had sufficient number of rotavirus cases to perform the described activity. In 2008, no other sites had identified rotavirus cases besides the proposed vendor. Identifying rotavirus cases-patients during the current 2009 rotavirus season is crucial to estimate the effectiveness of the vaccine. Note 22 applies herein. The statutory authority permitting other-than-full-and-open competition is 41 U.S.C., 253(c)(1): FAR 6.302-1. Only one responsible source and no other services will satisfy agency requirements. Interested persons may identify their interest and capability to respond to the requirement. This notice is not a request for competitive proposals. A determination by the Government not to compete this proposed contract will be based on responses to this notice and is solely within the discretion of the government. Information received will be considered solely for informational purposes. This procurement is not set-aside for small business. For contractual questions contact Maria Shamburger by email at heg9@cdc.gov

Rotavirus Vaccination Program

Department of Health and Human Services, Centers for Disease Control and Prevention | Published June 18, 2008  -  Deadline July 3, 2008
cpvs

General Information Document Type: Presolicitation Solicitation Number: 00HCVGEB-2008-56718 Posted Date: June 18, 2008 Original Response Date: July 3, 2008 Current Response Date: July 3, 2008 Original Archive Date: July 3, 2008 Current Archive Date: July 3, 2008 Classification Code: B-Special studies and analysis not R&D Set Aside: N/A Naics Code: 541380-Testing Laboratories Contracting Office Address Department of Health and Human Services, Center for Disease Control and Prevention, Procurement and Grants Office (Atlanta), 2920 Brandywine Road, Room 3708, Atlanta, GA, 30341-4146 Description The Centers for Disease Control and Prevention intends to issue a a sole source firm fixed priced purchase order to Surveillance Data, Inc., 220 West Germantown Pike, Suite 14, Plymouth Meeting, Pa 94647. No other souce of data that is geographically diverse to meeting program needs in a timely manner is available, therefore SDI is the most relevant and best option. Naics code 541380 and size standard of $11.0 million dollars is applicable to this order. Delivery date is on or before July 22, 2008. Shipment will only be accepted Monday thru Friday from 8:00 a.m. to 4:30 p.m. EST with the exception of Federal Government holidays. The following items are needed by the Division of Viral Diseases(NCIRD/DVD) Rotavirus Vaccination Data - Quantity of 1 job The best way to complete this certification is to download the FAR Clauses (Volume II) at: http://www.arnet.gov/far, print out the clause 52.212-3, Offeror Representation and Certification, and fill in the appropriate blanks. An anticipated award date of July 22, 2008 is place. All responsible sources that can meet the above requirement may submit a quote, which will be considered by the Agency. All vendors need to be registered in the Central Contracting Registry (CCR) prior to award of a Federal contract. The preferred method for completing registration is via the World Wide Web at http://www.ccr.gov. A handbook and other information are available at the website, including information on how to obtain a DUNS number, which is required to begin the registration process.

R--Non-Personal Services for Transcriptomic analysis following dengue vaccination.

Department of the Army, U.S. Army Medical Research Acquisition Activity | Published June 4, 2015  -  Deadline June 25, 2015
cpvs

This is a combined synopsis/solicitation for commercial items prepared in accordance with the format in Subpart 12.6, as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; proposals are being requested and a written solicitation will not be issued. PLEASE SEE THE ATTACHE SOLICITATION FOR FULL DESCRIPTON OF REQUIREMENTS.

Title of Project: Evaluating the Association between Parental Attitudes about Vaccines and Childhood and Adolescent Vaccination Status, 2010

Department of Health and Human Services, Centers for Disease Control and Prevention | Published November 30, 2009  -  Deadline December 17, 2009
cpvs

THIS NOTICE IS PROVIDED FOR INFORMATIONAL PURPOSES ONLY UNDER THE AMERICAN RECOVERY AND REINVESTMENT ACT PROGRAM. THIS OPPORTUNITY IS AVAILABLE ONLY TO CONTRACTORS UNDER GENERAL SERVICES ADMINISTRATION, GSA FEDERAL SUPPLY SCHEDULE 874-3 - MISSION ORIENTED BUSINESS INTEGRATED SERVICES (MOBIS) - SURVEY SERVICES. This will be funded in whole by the American Recovery and Reinvestment Act of 2009, and is subject to the reporting requirements of the Act. The purpose of this action is to address the need of the CDC for survey data on parental attitudes towards childhood and adolescent vaccines. These data will be used to evaluate the extent of parents' trust and acceptance of childhood and adolescent vaccines, and to examine how parents' attitudes about vaccines are associated with childhood and adolescent vaccination status. The Government anticipates awarding a fixed price task order under FAR 8.4 ordering procedures. This is not a request for competitive proposals; the solicitation will be issued to selected vendors in accordance with FAR 8.4 ordering procedures.

65--Vaccination workstation

Department of Veterans Affairs, Long Beach VANLO | Published October 4, 2010
cpvs

Awarded as lowest price technically acceptable.

Influenza Virus Vaccine

Department of Health and Human Services, National Institutes of Health | Published August 21, 2015  -  Deadline September 1, 2015
cpvs

This is a combined synopsis/solicitation for commercial items prepared in accordance with the format in Federal Acquisition Regulation (FAR) subpart 12.6, "Streamlined Procedures for Evaluation and Solicitation for Commercial Items," as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; quotations are being requested, and a written solicitation document will not be issued. The solicitation is being issued using simplified acquisition procedures under the authority of FAR 13.5 Test Program for Certain Commercial Items. The solicitation document and incorporated provisions and clauses are those in effect through Federal Acquisition Circular (FAC) 2005-83, effective August 3, 2015. This combined synopsis/solicitation is set aside for Small Business only. Only Small Businesses under the associated the associated North American Industrial Classification System (NAICS) code are invited to submit quotes. The associated NAICS code for this procurement is 325412 with a small business size standard of 750 employees. The National Institutes of Health, Office of Purchasing and Contracts, is seeking a vendor to provide 10,100 doses of Fluzone Quadrivalent flu vaccine from the U.S. Manufacturer for the NIH Vaccination Program. See Combined Synopsis/solicitation including the Influenza Virus Vaccine Statement of Work attached herein. All Contractors operating as small businesses are encouraged to provide a quotation/offer for the items listed in the tables below. ELECTRONIC OFFERS. The offeror shall submit electronic offers in response to this solicitation unless otherwise specified herein. The offer must arrive by 9:00 a.m. September 01, 2015 to the following email address: Lisa.Schaupp@nih.gov .

National Immunization Survey

Department of Health and Human Services, Centers for Disease Control and Prevention | Published April 3, 2017
cpvs

The Centers for Disease Control and Prevention (CDC) intends to issue a full and open competition Request for Proposal (RFP) to support National Center for Immunizations and Respiratory Diseases (NCIRD) /Influenza Division. This will be a follow-on requirement to a previous National Immunization Survey Indefinite Delivery Indefinite Quantity (IDIQ) single award contract. It is anticipated that the resultant contract will be cost plus fixed fee and firm fixed price types. The period of performance of sixty (60) months is anticipated. The applicable NAICS code is 541910. The RFP will be posted on FedBizOpps and is expected to be released on or about May 15, 2017. Interested parties are responsible for checking the website regularly for release of the RFP and for other procurement-related documents. TELEPHONE CALLS WILL NOT BE ACCEPTED. The information provided in this pre-solicitation is for information purposes only. If there are any differences in the information provided here and the actual solicitation when released, the information provided in the actual solicitation shall govern. Background and Need The National Center for Immunization and Respiratory Diseases (NCIRD), Immunization Services Division (ISD), a center of the Centers for Disease Control and Prevention (CDC) of the United States Department of Health and Human Services (DHHS), require the planning and conduct of the National Immunization Survey (NIS) and related tasks.Vaccination for childhood diseases has proven to be one of the most effective public health measures available. This has been shown through the reduction in the incidence of vaccine preventable diseases throughout the United States. The adoption of laws for vaccinations as a requirement for school entry has been credited with high vaccination levels in this population. The 1989-1990 measles outbreak in the United States brought into focus the public health problem of under-vaccination among preschool children. Healthy People 2020 objectives for immunization and infectious diseases include reaching high proportions of children receiving recommended vaccinations by their second birthday and adolescents receiving additional recommended vaccinations by 13-15 years of age. In 1992, the 50 States and 28 local areas were awarded grants to improve the vaccination levels of children by their second birthday, and improve related service delivery, information and education, and assessment activities. Each grantee area developed an Immunization Action Plan (IAP) for the use of these funds and proposed approaches to improve the immunization delivery system in their areas (referred to as IAP areas). Determination of vaccination levels and changes over time was necessary for monitoring the success of the grants to these IAP areas. The NIS was established in response to the immediate and continuing need for quality and timely data pertaining to the vaccination coverage of pre-school children across the United States. Beginning in 1994, in addition to national vaccination coverage data collected via the National Health Interview Survey (NHIS), the NCHS and the National Immunization Program (NIP), which is now NCIRD, began collecting vaccination information for children 19-35 months in these 78, non-overlapping geographic IAP areas across the United States via the NIS, based on a random-digit-dial (RDD) landline telephone sample of households with immunization provider record check verification. This information has been used to monitor the need for vaccinations among 19-35 month old children in each IAP area and nationally in the civilian noninstitutionalized population. During 2005 and 2006, some of the non-grantee IAP areas were rotated off the survey (no longer oversampled) to allow new selected sub-state areas to be oversampled. Starting with 2007 data collection, the 22 IAP areas that did not receive direct Section 317 immunization grant funding from CDC were no longer automatically oversampled. Starting in 2007, state immunization programs were offered the opportunity to direct grant funds to oversample sub-state areas of their choice. This change resulted in core NIS data collection in 56 non-overlapping, geographically defined Local Sampling Areas (LSAs), including the 50 states and six urban areas that receive Section 317 immunization grant funding directly from CDC (District of Columbia; City of Chicago, IL; City of New York, NY; Philadelphia County, PA; Bexar County, TX; and City of Houston, TX). Additional sub-state areas and U.S.-affiliated jurisdictions may be added and may vary from year to year. By 2006, three new vaccines had been licensed and recommended for routine use in adolescents: meningococcal conjugate vaccine (MCV4), tetanus, diphtheria, acelluar pertussis (Tdap), and (for girls) quadrivalent human papillomavirus vaccine (HPV4). In the 4th quarters of 2006 and 2007, the NIS-Teen was conducted using the NIS sampling frame and methods to estimate vaccination coverage among adolescents aged 13-17 years. In 2008, the NIS-Teen sample was expanded to provide estimates for the 56 core NIS LSA's, and starting in 2009 additional sub-state areas were added at the request of some states. It is possible that CDC may need to change the age range of children included in the NIS in the future.The NIS has periodically added topical modules to the household interview to collect additional vaccine-related information as needed by CDC. A health insurance module to determine status of eligibility for the Vaccines for Children Program (VFC) was added in 2003 and became part of the core NIS survey in 2006. Recent modules have included expanded questions related to socioeconomic status and parental hesitancy to vaccinate their children. Surveys of adult vaccination were conducted in 2003, 2004 and 2007. During October 2009-June 2010, questions were asked of children of all ages identified during NIS screening to monitor seasonal and monovalent 2009 (H1N1) influenza vaccinations. These data were combined with a stand-alone dual frame landline and cell phone RDD influenza vaccination survey to comprise the National 2009 H1N1 Flu Survey (NHFS). For subsequent influenza seasons, this data collection, called NIS-Flu, has continued each October through June for children aged 6 months through 17 years. Collectively, the data collected from the same sample frame consisting of children 19-35 months (NIS core), 13-17 years (NIS-Teen), and 6 months - 17 years (NIS-Flu) is described as the NIS Family of Surveys.Research to improve the validity of survey estimates and effectiveness and efficiency of survey operations has been integral to the NIS since its inception. In recent years, declining willingness of the public to participate in surveys and changes in households' use of the telephone has resulted in declining response rates in the NIS and other surveys. Of particular concern is the increasing prevalence of households that have substituted their landline telephone for wireless service only. Over 40% of children aged 19-35 months may not be reachable by a landline survey. Addition of a cellular telephone sampling frame was piloted in 2010 and incorporated into the NIS starting in 2011 (http://www.cdc.gov/vaccines/imz-managers/coverage/nis/child/dual-frame-sampling.html). Other research has investigated the potential role of Immunization Information Systems (IIS) in the conduct of the NIS. IIS are confidential, population-based, computerized databases that record all immunization doses administered by participating providers to persons residing within a given geopolitical area. At the point of clinical care, an IIS can provide consolidated immunization histories for use by a vaccination provider in determining appropriate client vaccinations. At the population level, an IIS provides aggregate data on vaccinations for use in surveillance and program operations, and in guiding public health action with the goals of improving vaccination rates and reducing vaccine-preventable disease. IIS exist in most states, but vary in their level of child and provider participation, completeness of vaccination histories, and completeness and accuracy of household contact information. With continued development of IIS and increased use of electronic medical record systems and their integration into IIS, they may eventually replace the role of NIS in providing timely, valid and comparable estimates of vaccination coverage across state and local areas. In the shorter term, NIS and NIS-Teen samples have been matched to selected IIS to compare vaccination histories reported by both, and the potential use of IIS as a sampling frame, as a supplement to or in place of a telephone sample, has also been evaluated. Substantial efficiencies could be gained using IISs to supplement or replace the current NIS RDD telephone sampling frame. Further work is needed to define when an IIS is ready to be used as a sample frame, identify legal and policy barriers to data sharing, and assess willingness and resources needed by states to participate. The potential role of IIS to improve the efficiency of the NIS provider record check has also been evaluated.Project Objective The NIS contract will obtain a contractor to conduct the NIS and other related research tasks through the issuance of individual task orders. The objective of the NIS is to produce annual estimates of the proportion of noninstitutionalized children 19 through 35 months and 13 through 17 years receiving vaccinations recommended by the Advisory Committee for Immunization Practices (ACIP), in each of the nonoverlapping LSAs. It is also intended to describe sociodemographic disparities in vaccination coverage, factors that influence the vaccination status of children, the uptake of newly recommended vaccines, and how information about immunization is understood by the public. The objective for other related research is to: assess influenza vaccination utilization and related information during annual influenza seasons; assess additional vaccination-related information from children or adults of any age in response to emerging program needs; and improve efficiency, quality and validity of NIS.Scope of Work Project objectives will be achieved through issuance of firm fixed price or cost plus fixed fee task orders to conduct survey activities that are organized into the following subject areas: a. NIS Core. Collection of vaccination data for children aged 19-35 months in each of at least 56 state and local areas of the United States. b. NIS-Teen. Collection of vaccination data for adolescents aged 13-17 years using the same sample as the NIS, in each of at least 56 state and local areas of the United States. c. Influenza Vaccination Surveys (children 6 months to 7 years). Collection of data related to influenza vaccination among persons of all ages. d. Optional Vaccination-related Modules. Collection of additional vaccination-related data for children eligible for the NIS or NIS-Teen, NIS-Flu or from other age groups of children or adults, using the same sample as the NIS, or using separate, stand-alone sampling frames. e. Operational Methods Research. Evaluation, research and experiments to improve efficiency, quality and validity of NIS. Period of Performance The period of performance for issuance of task orders against the IDIQ contract is a base period of one year and four one-year option periods. Individual periods of performance will be specified per each task order. Technical Requirements Task orders will be issued by NCIRD under the following general categories: a. NIS Core. Collection of vaccination data for children aged 19-35 months in each of at least 56 state and local areas of the United States. The NIS Core Task Orders will involve: 1) the design and conduct of quarterly/annual surveys to be fielded in each of the LSAs collecting data from the families of age-eligible children in RDD interviews for specified data years; 2) collecting data from the medical providers reported for those children (with oral consent from the parent or guardian); 3) combining the information from the responding providers and families to produce improved vaccination estimates comparable over time; 4) other data collections; 5) performing descriptive analyses of the data collected; 6) preparing computer files from edited survey data and reports documenting the files and the survey data collection methods and process results, and 7) performance monitoring and quality improvement efforts to assess and improve data quality and survey efficiency. A NIS data year refers to one calendar year, January 1 - December 31, during which quarterly samples of landline and cellular telephone numbers are dialed to identify households with age-eligible children and conduct NIS interviews. Associated with each data year are approximately three prior months for planning (October - December), 12 months for household data collection, and approximately nine subsequent months to complete household interviews, complete follow-up of medical providers, prepare and deliver restricted access and public use data files, and final reports. For example, NIS data year 2018 includes activities that would span from approximately October 2017 through December 2019. NIS data year 2019 would span from approximately October 2018 through December 2020. Thus, activities associated with separate Task Orders for consecutive NIS data years would overlap in their period of performance. b. NIS-Teen. Collection of vaccination data for adolescents aged 13-17 years using the same sample as the NIS, in each of at least 56 state and local areas of the United States. Survey procedures are generally similar to those required to conduct the core NIS. c. Influenza Vaccination Surveys (children 6 months to 7 years). Collection of data related to influenza vaccination among persons of all ages. Task orders in this category may include influenza modules asked of children of any age identified during NIS screening, and general population surveys using an independent sample conducted continuously or periodically during the vaccination period, typically during October through June. CDC may use this contract for annual monitoring of influenza vaccination, with expanded approaches implemented as needed in emergent situations (e.g., pandemic influenza, shortage of influenza vaccine). d. Optional Vaccination-related Modules. Collection of additional vaccination-related data for children eligible for the NIS or NIS-Teen, or NIS-Flu from other age groups of children or adults, using the same sample as the NIS, or using separate, stand-alone sampling frames. Short (e.g., approximately 5 minutes) survey modules may be added to the end of the NIS, NIS-Teen, or NIS-Flu survey to collect additional vaccination related information (e.g., parental attitudes toward childhood vaccination). Task orders in this category may also include vaccination-related surveys using the NIS sampling frame, or separate, standalone sampling frames, to obtain parental information regarding vaccination of children of any age, or to obtain information from persons ≥18 years about their own vaccination-related behavior. e. Research Tasks. Evaluation, research and experiments to improve efficiency, quality and validity of NIS. Task orders in this category may include experiments to test modifications of survey instruments, survey operations and procedures, designing more efficient or valid sample designs (e.g., improved telephone sample design, switch to an address-based sample frame, or incorporating IIS as a NIS sample frame), and matching of NIS and NIS-Teen samples with IIS to evaluate completeness of IIS and NIS vaccination data. To the extent possible, changes in NIS design, methods, and operations are tested and evaluated before and after implementation, to ensure continuity in validity of estimates over time. In general, the contractor's responsibilities include such activities as:• Questionnaire design and testing;• Survey instrument modification if necessary and approved by CDC;• Sampling plan, design, and selection;• Preparation of the survey questionnaire(s) and other necessary data collection materials;• Recruitment, training and performance monitoring of interviewers;• Administration of telephone, mail surveys, and web surveys for providers;• Development of weighting procedures and implementation of estimators;• Design and implementation of quality control procedures;• Conversion of data on paper forms into machine readable form;• Preparation of field and methodological reports;• Preparation of verified, edited, and documented data files (on tape or other electronic format acceptable to the Contracting Officer's Representative {COR});• Preparation of materials for submission to the ERB;• Methodological Studies; and• Other activities essential for the successful completion of the project. Place of Performance Services will be performed at vendor specified site in the United States. All aspects of work related to this contract must be performed in the U. S., this includes work performed by the Contractor and any sub-contractors. For individual task orders, some work may be conducted in the U.S.-affiliated jurisdictions (e.g., United States Virgin Islands, Guam, Puerto Rico) at the specific request of the COR.Reporting Schedule Contractor reporting requirements will be defined in each individual task order. Reports may include weekly, monthly, or quarterly reports, along with a final report. Travel Any required travel will be identified on individual task orders as necessary. The Contractor shall coordinate all travel requirements with the CDC Contracting Officer's Representative (COR) and obtain written approval from the Contracting Officer prior to beginning such travel.Government will reimburse the Contractor for travel related costs. The Contractor shall submit receipts for airfare, lodging, car rentals, and other incidental travel-related expenses. Travel costs shall not exceed the maximum per diem rates set forth in the Federal Travel Regulation (FTR). The FTR per diem rates and regulations can be found at the following website: http://www.gsa.gov/portal/content/104877Training The Contractor, at its own expense, shall perform training for their professional staff associated with required competencies for each task. The Government will provide orientation and training on specific department, unit, site, programs or education requirements, policies, and procedures peculiar to the work to be performed by the Contractor and unique to CDC operations if required for specific tasks. The Government will not authorize training for Contractor employees to attend seminars, symposiums, or user group conferences unless determined that attendance is mandatory for the performance of task requirements and such training is approved in advance by the Contracting Officer. The Contractor shall assume full responsibility for keeping Contractor employees abreast of advances in state-of-the-art technologies.  

A Prospective Clinical Trial to Determine the Seroconversion and Immunogenicity of Hepatitis A Vaccine Starting at 15 Days Post-Vaccination in Persons Age > 40 Years

Department of Health and Human Services, Centers for Disease Control and Prevention | Published May 12, 2014
cpvs

The Centers for Disease Control and Prevention (CDC) intends to issue a Request for Proposal (RFP) to support the National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP). This will be a new requirement. It is anticipated that the resultant contract will be firm-fixed price and will have a period of performance of thirty-six (36) months. The applicable NAICS code is 541712 with a size standard of 500 employees. The RFP will be posted on FedBizOpps and is expected to be released on or about June 2, 2014. Interested parties are responsible for checking the website regularly for release of the RFP and for other procurement-related documents. TELEPHONE CALLS WILL NOT BE ACCEPTED. The information provided in this pre-solicitation is for information purposes only. If there are any differences in the information provided here and the actual solicitation when released, the information provided in the actual solicitation shall govern. The CDC/NCHHSTP is seeking technical assistance from an offeror with expertise in designing and conducting clinical vaccine trials among older adults to assess the immune response to hepatitis A vaccine in accordance with possible use for post-exposure prophylaxis. The offeror will conduct a clinical trial with approval by the CDC and local Institutional Review Boards (IRB) and in compliance with IRB protocol and other appropriate HHS/CDC requirements for scientific research. Data are lacking on the effectiveness of hepatitis A vaccine for post-exposure prophylaxis among adults 40 years and older. The results of this study will inform development of updated U.S. post-exposure prophylaxis recommendations affecting adults > 40 years of age. The current Advisory Committee on Immunization Practices (ACIP) recommendations state that for persons aged > 40 years, immunoglobulin (IG) is preferred; vaccine can be used if IG cannot be obtained. Hepatitis A vaccine generally is more readily available than IG for immediate use after exposure. Hepatitis A vaccination has the advantage over IG of inducing long-term protection and potential individual benefits, such as knowledge of protection against future exposures. The primary objective is to determine the immunogenicity and safety of hepatitis A vaccination among healthy susceptible adults age ≥ 40 years by decade of life in comparison to a control group of healthy susceptible adults age 30-39 years. Eligible offerors must have the access and capability to conduct research in a clinical setting, including appropriate confidentiality and protection of human subject assurances, and demonstrated experience with applying for and receiving local IRB approval for clinical trials. Eligible offerors will recruit subjects, determine eligibility of subjects, obtain blood samples, perform vaccinations, monitor safety, send aliquoted blood samples to the CDC Hepatitis Reference Laboratory for analysis, inform subjects of the results or laboratory testing, and document immunogenicity. CDC has the following objectives: 1) To write a protocol consistent with the Office for Human Research Protections (OHRP) guidelines for conducting clinical research for a vaccine trial, and that will meet local and federal requirements for IRB approval. 2) To recruit an appropriate study population for the trial as specified in the performance work statement, including obtaining informed consent and collecting a medical history. 3) To collect and properly store blood samples (http://www.cdc.gov/hepatitis/HEV/PDFs/HRL_PCRSampleHndlgShpg_20080615.pdf), and ensure privacy and confidentiality; properly store vaccines (http://www.cdc.gov/vaccines/pubs/pinkbook/downloads/vac-storage.pdf). 4) To have laboratory capabilities to conduct laboratory tests for antibody titers, serology, and liver function. 5) To provide clinical staff who meet legal and licensure qualifications ensuring the ability to administer vaccine. 6) Demonstrated experience to perform scientific data analysis and prepare manuscripts for peer reviewed scientific journals. The offeror shall furnish all the necessary personnel, facilities, supplies, equipment, as appropriate to provide CDC with the required scientific, technical, and operational services, within the general work parameters set forth in the statement of work.

A Prospective Clinical Trial to Determine the Seroconversion and Immunogenicity of Hepatitis A Vaccine Starting at 15 Days Post-Vaccination in Persons Age ≥ 40 Years

Department of Health and Human Services, Centers for Disease Control and Prevention | Published May 12, 2014
cpvs

The Centers for Disease Control and Prevention (CDC) intends to issue a Request for Proposal (RFP) to support the National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP). This will be a new requirement. It is anticipated that the resultant contract will be firm-fixed price and will have a period of performance of thirty-six (36) months. The applicable NAICS code is 541712 with a size standard of 500 employees. The RFP will be posted on FedBizOpps and is expected to be released on or about June 2, 2014. Interested parties are responsible for checking the website regularly for release of the RFP and for other procurement-related documents. TELEPHONE CALLS WILL NOT BE ACCEPTED. The information provided in this pre-solicitation is for information purposes only. If there are any differences in the information provided here and the actual solicitation when released, the information provided in the actual solicitation shall govern. The CDC/NCHHSTP is seeking technical assistance from an offeror with expertise in designing and conducting clinical vaccine trials among older adults to assess the immune response to hepatitis A vaccine in accordance with possible use for post-exposure prophylaxis. The offeror will conduct a clinical trial with approval by the CDC and local Institutional Review Boards (IRB) and in compliance with IRB protocol and other appropriate HHS/CDC requirements for scientific research. Data are lacking on the effectiveness of hepatitis A vaccine for post-exposure prophylaxis among adults 40 years and older. The results of this study will inform development of updated U.S. post-exposure prophylaxis recommendations affecting adults > 40 years of age. The current Advisory Committee on Immunization Practices (ACIP) recommendations state that for persons aged > 40 years, immunoglobulin (IG) is preferred; vaccine can be used if IG cannot be obtained. Hepatitis A vaccine generally is more readily available than IG for immediate use after exposure. Hepatitis A vaccination has the advantage over IG of inducing long-term protection and potential individual benefits, such as knowledge of protection against future exposures. The primary objective is to determine the immunogenicity and safety of hepatitis A vaccination among healthy susceptible adults age ≥ 40 years by decade of life in comparison to a control group of healthy susceptible adults age 30-39 years. Eligible offerors must have the access and capability to conduct research in a clinical setting, including appropriate confidentiality and protection of human subject assurances, and demonstrated experience with applying for and receiving local IRB approval for clinical trials. Eligible offerors will recruit subjects, determine eligibility of subjects, obtain blood samples, perform vaccinations, monitor safety, send aliquoted blood samples to the CDC Hepatitis Reference Laboratory for analysis, inform subjects of the results or laboratory testing, and document immunogenicity. CDC has the following objectives: 1) To write a protocol consistent with the Office for Human Research Protections (OHRP) guidelines for conducting clinical research for a vaccine trial, and that will meet local and federal requirements for IRB approval. 2) To recruit an appropriate study population for the trial as specified in the performance work statement, including obtaining informed consent and collecting a medical history. 3) To collect and properly store blood samples (http://www.cdc.gov/hepatitis/HEV/PDFs/HRL_PCRSampleHndlgShpg_20080615.pdf), and ensure privacy and confidentiality; properly store vaccines (http://www.cdc.gov/vaccines/pubs/pinkbook/downloads/vac-storage.pdf). 4) To have laboratory capabilities to conduct laboratory tests for antibody titers, serology, and liver function. 5) To provide clinical staff who meet legal and licensure qualifications ensuring the ability to administer vaccine. 6) Demonstrated experience to perform scientific data analysis and prepare manuscripts for peer reviewed scientific journals. The offeror shall furnish all the necessary personnel, facilities, supplies, equipment, as appropriate to provide CDC with the required scientific, technical, and operational services, within the general work parameters set forth in the statement of work.

Influenza Vaccine for NIH Clinical Center Program

Department of Health and Human Services, National Institutes of Health | Published May 18, 2017  -  Deadline May 30, 2017
cpvs

This is a combined synopsis/solicitation for commercial items prepared in accordance with the format in Federal Acquisition Regulation (FAR) subpart 12.6, "Streamlined Procedures for Evaluation and Solicitation for Commercial Items," as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; quotations are being requested, and a written solicitation document will not be issued. The solicitation document and incorporated provisions and clauses are those in effect through Federal Acquisition Circular (FAC) 2005-95, Effective: 19 Jan 2017 (Includes FAC 2005-94 Effective 19 Jan 2017). The associated North American Industrial Classification System (NAICS) code for this procurement is 325412 with a small business size standard of 1250 employees. This acquisition is set aside to small business. Responses are due by 11:00 a.m. E.T., May 30, 2017.  Quotations should be emailed to the Contract Specialist, Lisa Schaupp (Lisa.Schaupp@nih.gov) prior to the due date and time.  The National Institute of Health, Office of Purchasing and Contracts, is seeking to obtain a supply of flu vaccine, manufactured by a U.S. Flu vaccine manufacturer to fulfill the 2017-2018 Influenza Vaccination program. Types of vaccine and quantities are listed in the pricing tables below. The Government anticipates awarding a Purchase Order for this supply. Additional quantities astpre-negotiated prices may be purchased should there be additional need. The vaccine type is required to be consistent with previous orders. Please see the Statement of Work (SOW) for details of the requirement.

65--VACCINATIONS

Department of the Navy, Naval Supply Systems Command | Published May 13, 2010  -  Deadline May 18, 2010
cpvs

Yellow Fever Vaccination. To be negotiated on a sole source basis with Sanofi Pasteur per FAR 6.302. Interested persons may identify their interest and capability by responding to the requirement or submitting quotations prior to offer due date, which will normally be considered solely for the purpose of determining whether to conduct a competitive procurement. A determination not to compete this action based upon responses received to this notice is solely within the discretion of the government. The sole source is based on no other known manufacturers and delivery timeframe. This solicitation and any subsequent amendments will be posted to the NECO web site: https://www.neco.navy.mil. Electronic submission of quotes is available through the NECO web site.

Journal Supplement - Increasing HPV Vaccine Coverage

Department of Health and Human Services, Centers for Disease Control and Prevention | Published June 16, 2016  -  Deadline July 2, 2016
cpvs

The Centers for Disease Control and Prevention, NCIRD/ISD, 1600 Clifton Rd. NE, Mailstop A19, Atlanta, GA, 30333, hereby announces its intent to issue a sole source contract to Academic Pediatric Association 6728 Old Mclean Village Dr McLean, VA, 22101 to publish a 100-page special supplement on improving HPV vaccination coverage levels in the Academic Pediatrics Journal. NAICS Code: 511120 Period of Performance: 07/20/2016 to 11/30/2017 The statutory authority permitting other than full and open competition is 41 U.S.C. 253(c)(1) as cited in FAR 13.106-1(b)(1)(i). The Academic Pediatric Association is the sole publisher of the Academic Pediatric Journal and the only provider of the service that is required. Responsible sources that believe they possess the expertise and capabilities identified above are encouraged to submit to the Contracting Officer within 15 days from the posting date of this notice, their written capabilities statement, proposal or quotation which shall be considered by the agency for future procurement. Please forward the capability statement and/or pricing information to Michael Harwell, Contracting Specialist, 200-Q-65324, Centers for Disease Control, Procurement and Grants Office, ATTN: Michael Harwell, MS: K14, 2920 Brandywine Road, Atlanta, GA 30341. All vendors must be registered in the System for Award Management (SAM) prior to an award of a federal contract. The website is: www.sam.gov. This is a posting of a sole source award to Academic Pediatrics Association and is not a request for competition.  

Vaccine Development (CVA campy plates)

Department of the Navy, Bureau of Medicine and Surgery | Published February 24, 2016  -  Deadline March 2, 2016
cpvs

U.S. Naval Medical Research Unit No. 6 (NAMRU-6) is seeking laboratory reagents to perform pre-clinical vaccine trials in non-human vaccine to protect against enteric bacterial infections. This acquisition requires there search project include vaccination of non-human primates followed by a bacterial infection challenge event to determine protective efficacy of the vaccine.If capable sources are not identified through this notice, then NAMRU 6 intends to award a sole source contract under the authority of 13.106-1(b)(i) to Government Scientific Source, for the requirements of these products.Government Scientific Source is the only vendor able to supply reagents that are critical for our IACUC approved protocols under Bacteriology Vaccine Development Program that other companies from United States don't ship internationally due to restrictions. This pre-solicitation is not a request for competitive proposals and no solicitation document exists for the requirement. Sources interested in responding to this notice are required to submit a capability statement that includes management and technical data and cost information, in sufficient detail and with convincing evidence that clearly demonstrates the capability to perform the required work. Capability statements shall not exceed 5 (8.5 x 11 inch) pages using a font size no smaller than 10-point. All capability statements received by the due date of this notice will be considered by the Government. A request for documentation or additional information or submissions that only ask questions will not be considered as an affirmative response. A determination by the Government not to compete based on responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement or to proceed with a sole source contract.Capability statements are due by 12:00 PM Local Time, 02 March, 2016. Capability statements shall be submitted by e-mail ONLY as a Microsoft Word or Adobe PDF attachment to the following address: genaro.m.vasquez.fn@mail.mil Please use subject line "N44852GSS". Contracting Office Address: 3230 Lima Pl, Washington DC, 20521 United States Primary Point of Contact.: Martin Vasquezgenaro.m.vasquez.fn@mail.mil  
Categories
  United States - Show all countries
Atlanta, ga (117)Bethesda, md (83)Rockville, md (27)Robbins avenue philadelphia, pa (23)Philadelphia, pa (22)Washington, dc (17)Floor minneapolis, mn (13)Clay center, ne (12)Usa (11)Orient point, ny (9)Silver spring, md (7)Tbd (7)Mcclellan park, ca (6)Office of the chief procurement officer washington dc 20528 (6)Chandler street frederick, md (5)Contractor's facility (5)Atlanta, georgia (4)Contractor's premise (4)Draper, ut (4)Greenport, ny (4)Place of performance is unknown at this time (4)Battle creek, mi (3)Camp pendleton, ca (3)Frederick, md (3)Kansas street natick, ma (3)Multiple shipping information. (3)One block north of cermak hines, il (3)Perry point, md (3)Philadelphia, pa (3)San antonio, tx (3)Thomas johnson drive frederick, md (3)30341 (2)40550 route 25, orient point, new york (2)430 army dr rt 16 bldg 100 barrigada 2 96913 (2)Addis ababa (2)Apo apo ae 1 (2)Atlanta,, ga (2)Conus and territories (2)Camp pendleton, ca (2)Canton, ma (2)Cincinnati, oh (2)Columbus, oh (2)Contractor site (2)Davis, ca (2)Fpo, ap, 1 (2)Fort polk, la (2)Fort thompson, sd (2)Gaithersburg, md (2)Huntsville, al (2)Johnston, ia (2)Kansas city, mo (2)Lima, 1 (2)Mcclellan business park, ca (2)Multiple locations (2)Natick, ma (2)Oakland, ca (2)Place of performance is unknown at this time. (2)Roger brooke drive fort sam houston, tx (2)Street long beach, ca (2)Swiftwater, pa (2)Tucson, az (2)W iowa city, ia (2)Washington, dc (2)Washington, dc 20037 (2)Wagner, sd (2)Washington, dc 20037 (2)Washington, dc 20520 (2)Washington, dc 20522 (2)West, virginia (2)Contractor's premises (2)* see solicitation places of performance * (1), nj (1), tx (1)00000 (1)02139 (1)20817 (1)430 army drive, barrigada, gu 96913 (1)Ap, ca (1)Apo, 1 (1)Al udeid air base qatar (1)All locations from where offerors could ensure delivery of fresh human specimens (peripheral blood mononuclear cells) to the niaid-lmiv site in rockville, maryland, within two hours of initial processing . (1)All performance related to this requirement will be conducted at the contractor's facilities (1)Alto caballero, pa (1)Ames, in (1)Athens, ga (1)Atlanata, ga (1)Augusta, ga (1)Austin, tx (1)Awardee location (1)Barrigada, gu 96913 (1)Bethesda, md (1)Blm nm-oklahoma field ofc(nm004) (1)Blm nm-oklahoma field ofc(nm004)7906 e. 33rd street, suite 101tulsaok74145us (1)Blm nm-state ofc-santa fe(nm916) (1)Blm oc-noc svc & supply sec(oc663) (1)Baghdad, 1 (1)Baltimore, md (1)Beaufort, sc (1)Betesda, md (1)